Quadrivalent Influenza High-Dose Vaccine

BIOLOGICAL3 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

Influenza Immunization

Phase 1

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

CompletedNCT05553301

Sanofi Pasteur, a Sanofi CompanyInfluenza Immunization

Start: 2022-10-03End: 2024-01-19Updated: 2025-01-24

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

CompletedNCT05650554

Sanofi Pasteur, a Sanofi CompanyInfluenza Immunization

Start: 2022-12-12End: 2024-04-02Updated: 2025-03-19

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

CompletedNCT06361875

Sanofi Pasteur, a Sanofi CompanyInfluenza Immunization

Start: 2024-04-01End: 2025-06-09Updated: 2025-06-19